Nvidia gains 1.6% as Roche deploys 3,500 Blackwell chips for drug discovery
Healthcare partnership builds on $1 trillion revenue opportunity CEO Jensen Huang outlined for Blackwell and Rubin chips through 2027
Nvidia shares rose 1.6% on Tuesday as the chipmaker expanded its artificial intelligence footprint in healthcare through a major deployment with pharmaceutical giant Roche, which is installing more than 3,500 Blackwell GPUs across facilities in the United States and Europe.
The stock closed at $183.19, after reaching an intraday high of $183.73, marking the company's latest move to capitalize on what Chief Executive Jensen Huang described as a at least $1 trillion revenue opportunity for its AI chips through 2027. The ambitious forecast, up from a previous $500 billion projection through 2026, is driven by demand for Nvidia's next-generation Blackwell and Rubin chip architectures as AI applications expand from model training to inference and agentic AI.
The Roche deployment, announced at Nvidia's GTC 2026 conference, represents what the Swiss pharmaceutical company calls the largest announced GPU footprint in the pharmaceutical industry. The infrastructure, which includes 2,176 new Blackwell GPUs added to existing systems, will operate across hybrid cloud and on-premises environments as Roche builds what it terms "AI factories" to accelerate drug discovery and diagnostics development.
"We're excited to innovate at the intersection of science and technology to accelerate drug and diagnostic solutions development," said Wafaa Mamilli, Roche's chief digital and technology officer, in Nvidia's official announcement. "When we talk about collapsing time, we're really talking about the patients and their families who are waiting."
The partnership builds on a collaboration that began in 2023 and is already delivering results. Nearly 90% of Genentech's eligible small-molecule programs have integrated AI, with one oncology program experiencing a 25% increase in molecule design speed, according to Roche. The expanded infrastructure will support biological and molecular foundation models, accelerate Genentech's Lab-in-the-Loop strategy, and enable digital twins of manufacturing facilities using Nvidia's Omniverse libraries—including a new GLP-1 production facility in North Carolina.
The market response has been cautiously positive. Goldman Sachs reiterated its 'Buy' rating on Nvidia on Tuesday, citing strong datacenter visibility. Among analysts covering the stock, 47 rate it a 'Buy' and 11 recommend 'Strong Buy', with an average target price of $267.54—more than 45% above current levels. Only two analysts hold a 'Hold' rating, while one recommends 'Sell'.
Despite the modest single-day gain, analysts view the healthcare expansion as strategically significant. Nvidia's revenue has surged 73.2% year-over-year to $215.9 billion over the trailing twelve months, with quarterly earnings growth of 95.6%. The company's market capitalization stands at $4.38 trillion, reflecting its dominant position in the AI infrastructure market.
The Roche announcement underscores Nvidia's broader strategy to diversify beyond its traditional customer base of hyperscale cloud providers and technology companies. As AI applications proliferate across industries, the company is targeting sectors including healthcare, automotive, and industrial manufacturing, where the computational demands of specialized workloads create new opportunities for its most advanced chips.
Nvidia's Blackwell platform, which began shipping in late 2024, and the upcoming Rubin architecture slated for release in the third quarter of 2026, are positioned to capture much of this growth. Huang told attendees at GTC 2026 that the shift from AI model training to inference—the deployment of AI models in production—represents the next phase of the AI boom.
For Roche, the investment in AI infrastructure reflects the accelerating digital transformation in pharmaceuticals, where computational approaches to drug discovery and development are becoming increasingly central. The company's use of AI spans its entire value chain, from early-stage research through manufacturing optimization and diagnostic applications.
"With high-quality data and smarter AI, we will be able to leverage those insights both in pharma as well as in our diagnostic divisions," Mamilli said, emphasizing that the partnership aims to compress the time required to bring new medicines to patients.
While Nvidia's stock has retreated from its 52-week high of $212.17 reached earlier this year, it remains well above its 200-day moving average of $177.39. The company trades at 36.8 times trailing earnings, a premium multiple that reflects both its dominant market position and investor expectations for continued growth as AI adoption expands across industries.